With an FDA-cleared innovative technology and a $14 price target, NRXS is an IPO with blue-sky potential.
Interest in this space may certainly intensify in the coming years and finding the companies that stand out now may be the most opportunistic.
Quickly get your eyes on NeurAxis, Inc. (NYSE: NRXS).
The company successfully completed its IPO and NYSE listing in August and may about to cause quite a commotion on Wall Street!
An analyst has said this IPO is “too compelling to ignore” and you may agree yourself after reading everything that this company has going on….
Trading at around $5, NRXS is a growing NYSE med-tech company that is commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults.
Neuromodulation treatments encompass a growing variety of methods that target the brain or nervous system at specific locations in the body.
Today, neuromodulation therapy is no longer a treatment of last resort. In fact, in its earlier implementation may even modify the trajectory of some chronic conditions.
Who are the players in the neuromodulation market?
The key players operating in the global neuromodulation market include Abbott, Boston Scientific Corporation, and Medtronic.
Could NRXS quickly rise to the ranks of these big players whose market caps are in the billions?
The stock currently has a “BULLISH” rating at StockTA.com and a $14 price target!
An analyst report from Goldman Smallcap Research (GSCR) on August 11th, 2023, models NRXS shares reaching $14 in the next six to twelve months.
Highlights from the report include:
You can read the full report HERE.
NRXS is dedicated to advancing science and leveraging evidence-based medicine to drive adoption of its IB-Stim™ therapy, which is its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, by the medical, scientific, and patient communities.
“A New Standard of Care”
The IB-Stim is a percutaneous electrical nerve field stimulator (PENFS) system intended to be used in patients 11-18 years of age with functional abdominal pain (FAP) associated with irritable bowel syndrome (IBS). The IB-Stim is intended to be used for 120 hours per week up to 3 consecutive weeks, through application to branches of Cranial Nerves V, VII, IX and X, and the occipital nerves identified by transillumination, as an aid in the reduction of pain when combined with other therapies for IBS.
Excitingly the IB-Stim™ is already FDA cleared for functional abdominal pain associated with irritable bowel syndrome (IBS) in adolescents 11-18 years old!
The company has generated over $8 million in revenue following the commercial launch of its proprietary IB-Stim™ technology. Sales began after the company had received the FDA clearance.
Brian Carrico, Chief Executive Officer commented, “We are pleased to have reached over $8 million in sales of our proprietary IB-Stim™ technology and look forward building upon our momentum with the funds received from our recently completed IPO. We continue to drive increasing adoption of our IB-Stim™ therapy, supported by a significant and growing body of positive clinical data and commercial large health insurance company payor support. We believe the growing movement of patients gravitating towards non drug related therapies, especially for children, will continue to fuel our rapidly increasing adoption and the market for our new indications.”
This is finally a non-drug alternative to reducing functional abdominal pain in patients who have IBS.
IBS, also known as spastic colon, colitis, nervous colon, and spastic bowel, is the most common cause of recurrent abdominal pain in children: 10 percent to 15 percent of children have IBS at some point.
NRXS’s IB-Stim is a non-surgical device that works by sending gentle electrical impulses into cranial nerve bundles located in the ear.
This stimulation targets brain areas involved in processing pain and aids in the reduction of functional abdominal pain associated with IBS.
Parents are leaving testimonials with NRXS that showcase how this technology has radically changed their hurting children’s lives.
NRXS is also conducting clinical trials with IB-Stim™ for four additional pediatric indications, including chronic nausea, post-concussion syndrome, chemotherapy induced nausea and vomiting, and cyclic vomiting syndrome.
NRXS’s IPO has been years in the making and it’s finally here!
Goldman Small Cap Research’s 6-12-month price target is $14 and is more than double the IPO price.
Goldman commented, “This newly trading IPO is too compelling to ignore. We believe NRXS is poised to revolutionize treatment strategies for children and adults who suffer from chronic and debilitating conditions. The Company boasts a first-mover advantage, strong IP, a total addressable market of $30B, and an FDA-cleared product that serves a major need in a badly underserved market. Plus, future, exponential top-line growth appears to be driven by a series of new insurance companies payer coverages, which exponentially increases the market opportunity with each new insurer.”
This may be the best time to have NRXS high on your radar! Start your research!
This release/advertorial is a commercial advertisement and is for general information purposes only. This is a Native Advertisement, meaning it is an informational paid marketing piece. WallStreetNation.com, owned and operated by Jade Cabbage Media, LLC d/b/a STOXmedia.com makes no recommendation that the securities of the companies profiled or discussed on this website should be purchased, sold, or held by viewers that learn of the profiled companies through our website.